Associations - TET2 mutation

TET2 mutation TET2 mutation	Myelodysplastic Syndrome MDS	TET2 mutation TET2 mutation	Myelodysplastic Syndrome MDS	ruxolitinib Sensitive: A2 - Guideline	ruxolitinib Sensitive: A2 - Guideline
TET2 mutation TET2 mutation	Acute Myelogenous Leukemia AML	TET2 mutation TET2 mutation	Acute Myelogenous Leukemia AML	azacitidine Sensitive: C2 – Inclusion Criteria	azacitidine Sensitive: C2 – Inclusion Criteria
TET2 mutation TET2 mutation	Myelodysplastic Syndrome MDS	TET2 mutation TET2 mutation	Myelodysplastic Syndrome MDS	azacitidine Sensitive: C2 – Inclusion Criteria	azacitidine Sensitive: C2 – Inclusion Criteria
TET2 mutation TET2 mutation	Myelodysplastic Syndrome MDS	TET2 mutation TET2 mutation	Myelodysplastic Syndrome MDS	pembrolizumab Sensitive: C3 – Early Trials	pembrolizumab Sensitive: C3 – Early Trials
TET2 mutation TET2 mutation	Acute Myelogenous Leukemia AML	TET2 mutation TET2 mutation	Acute Myelogenous Leukemia AML	venetoclax Sensitive: C3 – Early Trials	venetoclax Sensitive: C3 – Early Trials
TET2 mutation TET2 mutation	Acute Myelogenous Leukemia AML	TET2 mutation TET2 mutation	Acute Myelogenous Leukemia AML	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials	cytarabine / daunorubicin liposomal formulation Resistant: C3 – Early Trials
TET2 mutation TET2 mutation	Acute Myelogenous Leukemia AML	TET2 mutation TET2 mutation	Acute Myelogenous Leukemia AML	cytarabine Sensitive: C3 – Early Trials	cytarabine Sensitive: C3 – Early Trials
TET2 mutation TET2 mutation	Acute Myelogenous Leukemia AML	TET2 mutation TET2 mutation	Acute Myelogenous Leukemia AML	quizartinib Sensitive: C3 – Early Trials	quizartinib Sensitive: C3 – Early Trials
TET2 mutation TET2 mutation	T Cell Non-Hodgkin Lymphoma T Cell Non-Hodgkin Lymphoma	TET2 mutation TET2 mutation	T Cell Non-Hodgkin Lymphoma T Cell Non-Hodgkin Lymphoma	lenalidomide Resistant: C3 – Early Trials	lenalidomide Resistant: C3 – Early Trials
TET2 mutation TET2 mutation	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	TET2 mutation TET2 mutation	Peripheral T-cell Lymphoma Peripheral T-cell Lymphoma	CHOP Sensitive: C3 – Early Trials	CHOP Sensitive: C3 – Early Trials
TET2 mutation TET2 mutation	Myelodysplastic Syndrome MDS	TET2 mutation TET2 mutation	Myelodysplastic Syndrome MDS	sintilimab Sensitive: C3 – Early Trials	sintilimab Sensitive: C3 – Early Trials
TET2 mutation TET2 mutation	Acute Myelogenous Leukemia AML	TET2 mutation TET2 mutation	Acute Myelogenous Leukemia AML	talazoparib Sensitive: D – Preclinical	talazoparib Sensitive: D – Preclinical